Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

Zymeworks Inc. (NYSE:ZYME - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Zymeworks in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($0.51) per share for the quarter. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks' Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($1.17) EPS.

Several other equities research analysts have also recently issued reports on ZYME. Wells Fargo & Company raised their target price on Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research note on Thursday, December 19th. Lifesci Capital assumed coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price on the stock. JPMorgan Chase & Co. upgraded shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price target for the company in a research report on Monday, December 16th. HC Wainwright upped their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Monday, March 10th. Finally, Citigroup lifted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Zymeworks presently has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Remove Ads

Zymeworks Stock Up 2.6 %

Shares of Zymeworks stock traded up $0.33 during mid-day trading on Thursday, hitting $13.05. The stock had a trading volume of 525,246 shares, compared to its average volume of 476,128. The firm has a 50-day moving average of $13.71 and a two-hundred day moving average of $13.72. The firm has a market cap of $907.98 million, a P/E ratio of -8.70 and a beta of 1.13. Zymeworks has a 12-month low of $7.97 and a 12-month high of $17.70.

Insiders Place Their Bets

In other news, insider Paul Andrew Moore sold 21,200 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $14.92, for a total transaction of $316,304.00. Following the completion of the transaction, the insider now directly owns 14,741 shares of the company's stock, valued at approximately $219,935.72. The trade was a 58.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ecor1 Capital, Llc bought 22,689 shares of Zymeworks stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average cost of $13.08 per share, for a total transaction of $296,772.12. Following the acquisition, the director now owns 17,157,802 shares of the company's stock, valued at $224,424,050.16. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 1,560,890 shares of company stock worth $20,033,148 and sold 89,601 shares worth $1,336,847. Insiders own 1.92% of the company's stock.

Institutional Investors Weigh In On Zymeworks

A number of large investors have recently modified their holdings of ZYME. Polar Asset Management Partners Inc. acquired a new position in shares of Zymeworks during the fourth quarter worth $527,000. Voloridge Investment Management LLC purchased a new stake in Zymeworks during the 4th quarter worth about $640,000. Point72 Asset Management L.P. boosted its position in shares of Zymeworks by 565.8% during the 4th quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company's stock worth $4,833,000 after acquiring an additional 280,544 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Zymeworks by 0.4% in the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company's stock valued at $3,031,000 after acquiring an additional 886 shares during the last quarter. Finally, Deutsche Bank AG raised its position in shares of Zymeworks by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock worth $22,645,000 after acquiring an additional 17,849 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.